Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15062406 | 0.91 | FKBP1A (1.00) | FKBP1A | |
| SCHEMBL7761766 | 0.84 | FKBP1A (1.00) | FKBP1A | |
| SCHEMBL21241599 | 0.82 | FKBP1A (0.69) | FKBP1A | |
| SCHEMBL21241498 | 0.82 | FKBP1A (0.69) | FKBP1A | |
| SCHEMBL7507953 | 0.81 | FKBP1A (0.69) | FKBP1A | |
| SCHEMBL7220384 | 0.81 | FKBP1A (0.69) | FKBP1A | |
| SCHEMBL25755869 | 0.81 | FKBP1A (0.68) | FKBP1A | |
| SCHEMBL21241274 | 0.79 | FKBP1A (0.65) | FKBP1A | |
| SCHEMBL22861564 | 0.79 | FKBP1A (0.65) | FKBP1A | |
| SCHEMBL5966037 | 0.78 | FKBP1A (0.64) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376517-B1 | FOR TREATING VISION LOSS, PREVENTING VISION DEGENERATION, AND PROMOTING VISION REGENERATION (?NEOPSIS?) | GPI NIL HOLDINGS, INC. | 2002-04-23 | — | — | US | claimed |
| EP-0777478-B1 | INHIBITORS OF ROTAMASE ENZYME ACTIVITY | GUILFORD PHARM INC (US) | 2001-11-07 | — | — | EP | claimed |
| US-20010036947-A1 | Pipecolic acid derivative hair growth compositions and uses | GPI NIL HOLDINGS, INC. (US) | 2001-11-01 | — | — | US | claimed |
| US-6187784-B1 | ALOPECIA TREATMENT; FKBP-IMMUNOPHILIN AFFINITY | GPI NIL HOLDINGS, INC. | 2001-02-13 | — | — | US | claimed |
| US-5843960-A | Inhibitors of rotamase enzyme activity | GPI NIL HOLDINGS, INC. (US) | 1998-12-01 | — | — | US | claimed |
| US-6187784-B1 | ALOPECIA TREATMENT; FKBP-IMMUNOPHILIN AFFINITY | GPI NIL HOLDINGS, INC. | 2001-02-13 | — | — | US | disclosed |
| EP-1011650-A1 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | Amgen Inc., (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999014998-A2 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | AMGEN INC. (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036947-A1 | Pipecolic acid derivative hair growth compositions and uses | PIP5K1C, PIP4K2C, PIP5K1A | FKBP1A 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.